Certain Balance Sheet Components (Tables)

9 Months Ended

Dec. 31, 2022

Other Liabilities Disclosure [Abstract]

Schedule of Cash and Cash Equivalents

The following represents a reconciliation of cash and cash equivalents on the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the unaudited condensed consolidated statements of cash flows (in thousands):

	December 31,
	2022		2021
Cash and cash equivalents	$	250,590	$	457,742
Restricted cash (included in other assets)	6,168		10,100
Total cash, cash equivalents and restricted cash	$	256,758	$	467,842

Schedule of Inventory

Inventories consisted of the following (in thousands):

	December 31, 2022		March 31, 2022
Raw materials	$	15,597	$	663
Work in process	6,410		3,737
Finished goods	8,077		3,184
Total inventories	$	30,084	$	7,584

Schedule of Accrued Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	December 31, 2022		March 31, 2022
Accrued sales discounts, rebates, and allowances	$	36,858	$	19,390
Accrued compensation-related expenses	23,516		26,389
Accrued R&D expenses	10,244		6,955
Accrued commercial expenses	5,287		7,196
Accrued royalties payable to Takeda	4,400		2,470
Accrued other expenses	3,288		3,309
Accrued professional fees	3,265		1,340
Accrued income tax payable	475		720
Deferred product revenue	—		825
Total accrued expenses and other current liabilities	$	87,333	$	68,594